Cover Image

HR+/HER2- de novo metastatic breast cancer: a true peculiar entity?

De novo metastatic breast cancer (dnMBC) accounts for ~6-10% of all breast cancers and for ~30% of MBC with increasing incidence over time. Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) tumours are the most frequent subtype with a similar incidence to that o...

Full description

Saved in:
Bibliographic Details
Main Authors: Rosalba Torrisi (Author), Flavia Jacobs (Author), Chiara Miggiano (Author), Rita De Sanctis (Author), Armando Santoro (Author)
Format: Book
Published: BioExcel Publishing Ltd, 2023-03-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items